Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 40Neoplasms 8Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Quality of Life 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Gynecomastia 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Diseases 1Breast Cancer Subjects 1Breast Cancer Metastatic 1Breast Cancer Female 1Bone Density 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1

Interventions

ribociclib 1Tamoxifen 1Letrozole 1Goserelin 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer × Tamoxifen × Clear all
NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Novartis

Phase 1 Completed
88 enrolled
Breast

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡